Amgen quarterly results beat Wall Street estimates
The California-based biotech company's second-quarter revenue rose 9% from a year earlier to $9.2 billion. Adjusted earnings per share increased 21% to $6.02.
Analysts had expected an adjusted profit of $5.29 on revenue of $8.94 billion, according to LSEG data.
Second-quarter net earnings were $2.65 per share.
"We're delivering strong performance and reaching more patients with innovative medicines and biosimilars that address serious diseases," Amgen CEO Robert Bradway said in a statement.
Sales of cholesterol-lowering medication Repatha rose 31% to $696 million. Sales of bone drug Prolia fell 4% to $1.1 billion and the company said it expects further erosion this year due to new competition from biosimilars.
Adjusted operating expenses rose 8% from a year earlier, while research and development costs rose 18%.
The company said it expects to have data in the fourth quarter from two key mid-stage studies of its experimental weight-loss drug MariTide. One is testing the drug in obese or overweight adults with or without type 2 diabetes, while the second is looking at MariTide as a treatment for type 2 diabetes.
MariTide is an antibody linked to a pair of peptides that activate receptors for the appetite- and blood sugar-reducing hormone GLP-1 while simultaneously blocking a second gut hormone called GIP.
For the full year, Amgen slightly raised its financial outlook to adjusted earnings per share of $20.20 to $21.30 on revenue of $35 billion to $36 billion. It had previously forecast earnings of $20.00 to $21.20 per share on revenue of $34.3 billion to $35.7 billion. Analysts, on average, have estimated 2025 earnings of $20.91 per share on revenue of $35.4 billion.
The company said its 2025 outlook includes the impact of implemented tariffs, but does not account for any future levies, including potential sector-specific tariffs, or pricing actions that could be implemented in the future.
The pharmaceutical industry is facing intense pressure from U.S. President Donald Trump to lower prices that Americans pay for prescription medicines, while preparing for 15% tariffs on imports from the European Union.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
27 minutes ago
- Reuters
Delta, Aeromexico request extension to wrap up antitrust agreement
MEXICO CITY, Aug 12 (Reuters) - Carriers Delta (DAL.N), opens new tab and Aeromexico on Tuesday argued against winding down their antitrust agreement, as proposed by the U.S. Department of Transportation, while asking for an extension to do so if needed. The two, in a filing to authorities, requested the deadline be extended to March 28 of next year, the end of the sector's "winter season," from the current October 25.
Reuters
27 minutes ago
- Reuters
Australia's CBA posts record $6.7 billion full-year profit amid business lending push
Aug 13 (Reuters) - Commonwealth Bank of Australia ( opens new tab reported its best full-year cash earnings of A$10.25 billion ($6.69 billion) and a record dividend payout on Wednesday as the bank made a major push to gain business lending market share from its rivals. The bank's profits eclipsed a Visible Alpha consensus of A$10.24 billion and last year's A$9.84 billion, opens new tab. CBA, which is Australia's largest lender, declared a final dividend of A$2.60 per share, compared with A$2.50 apiece last year. Its full-year dividend payout of A$4.85 apiece is the highest ever and topped analysts' estimates. CBA's cash earnings rose on lending growth, especially in business banking, while underlying margins were stable. "It's a very strong result and shows that CBA is continuing to take market share in retail and business banking from its rivals," said Michael Haynes, equities analyst at Atlas Funds Management, which is a CBA investor. The bank has long been favoured by investors, with its shares up 17% this year, sharply outperforming its three main rivals. Interest rate cuts by the central bank lowered the bank's total loan impairment expenses as economic conditions improved. The Reserve Bank of Australia on Tuesday cut the official cash rate to 3.6% in its third interest rate reduction this year. "Many households have seen a rise in disposable incomes due to the recent relief from reduced interest rates, lower inflation and tax cuts," CBA said in its full-year earnings report. The bank warned the broader environment remained characterised by "a rise in global macroeconomic uncertainty, increased geopolitical risk and continued domestic competitive intensity", but said it maintained "prudent balance sheet settings over the long term". CBA said 85% of its customers were ahead on their mortgage repayments. However, despite the improving economic conditions, CBA said home loan payments delayed for more than 90 days jumped 5 basis points to 0.70%, the highest since at least 2018. The bank said some customers continued to be impacted by cost-of-living pressures. CBA, which underwrites a quarter of Australia's A$2.2 trillion mortgage market, saw its home and business lending grow 6.1% and 12.2%, respectively, in the past year, both outpacing the average growth seen by the overall banking system. Cash profit from business lending hit A$4.1 billion, up 8% on last year. The increase was the result of CBA making a concerted push to take market share from its major rivals. CBA's business lending share edged up to nearly 19% in the year, narrowing the gap with leader National Australia Bank ( opens new tab, which held about 21% in March. Competition in business lending is heating up as banks target traditional sector leader NAB on the back of volatility under its chief executive, Andrew Irvine. "Business banking is a higher margin business and CBA is moving more into that. Its priority is still to be number one for home lending and the icing on the cake is now business banking," said Atlas Funds' Haynes. CBA's net interest margin, a key measure of profitability, rose 9 basis points from last year to 2.08%. The common equity tier 1 capital ratio, a measure of spare cash, was flat from last year at 12.3%. The bank's chief executive, Matt Comyn, was paid A$7 million in the past year, down from A$8.9 million the previous year, according to the bank's annual report released on Wednesday. Comyn was granted a 14% increase in his base pay after no increases in the prior two years. The overall reduction in his salary was the result of increased holding and deferral periods introduced for shares granted in 2021, the annual report said. ($1 = 1.5323 Australian dollars)
Reuters
27 minutes ago
- Reuters
Singapore Telecommunications logs 14% rise in first-quarter profit
Aug 13 (Reuters) - Singapore Telecommunications ( opens new tab reported a 14% rise in first-quarter underlying profit on Wednesday, driven by strong performance from Australian unit Optus and contributions from regional associates including India's Bharti Airtel ( opens new tab. Southeast Asia's largest telecom operator reported an underlying net profit of S$686 million ($534.77 million) for the three-month period ended June 30, up from S$603 million a year earlier. That was largely in line with the consensus estimate of S$686.9 million, according to Visible Alpha. ($1 = 1.2828 Singapore dollars)
